Last $0.96 USD
Change Today +0.0616 / 6.86%
Volume 1.8M
NVIV On Other Exchanges
Symbol
Exchange
OTC US
As of 5:20 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

invivo therapeutics holdings (NVIV) Snapshot

Open
$0.94
Previous Close
$0.90
Day High
$1.05
Day Low
$0.92
52 Week High
02/27/14 - $2.67
52 Week Low
09/10/14 - $0.47
Market Cap
89.7M
Average Volume 10 Days
828.3K
EPS TTM
$-0.25
Shares Outstanding
93.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INVIVO THERAPEUTICS HOLDINGS (NVIV)

Related News

No related news articles were found.

invivo therapeutics holdings (NVIV) Related Businessweek News

No Related Businessweek News Found

invivo therapeutics holdings (NVIV) Details

Invivo Therapeutics Holdings Corp., a development stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injuries (SCI). The company is developing a biocompatible Neuro-Spinal Scaffold to treat acute SCI; and biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI. Its proprietary technologies incorporate intellectual property licensed under exclusive, worldwide license from Children’s Medical Center Corporation and the Massachusetts Institute of Technology, as well as intellectual property that has been developed internally in collaboration with advisors and partners. The company was founded in 2005 and is based in Cambridge, Massachusetts.

45 Employees
Last Reported Date: 03/17/14
Founded in 2005

invivo therapeutics holdings (NVIV) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: $1.0K
Compensation as of Fiscal Year 2013.

invivo therapeutics holdings (NVIV) Key Developments

InVivo Therapeutics Holdings Corp. Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial

InVivo Therapeutics Holdings Corp. (NVIV) announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center in Phoenix, AZ. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness. As previously stated and per FDA requirements, the company will follow the first enrolled subject for three months before re-opening enrollment.

InVivo Therapeutics Holdings Corp. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 03:00 PM

InVivo Therapeutics Holdings Corp. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 03:00 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States.

InVivo Therapeutics Holdings Corp. Appoints Daniel R. Marshak to Board of Directors

InVivo Therapeutics Holdings Corp. (NVIV) announced the appointment of Daniel R Marshak, PhD to its Board of Directors. Dr. Marshak most recently served as Senior Vice President and Chief Scientific Officer for PerkinElmer Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVIV:US $0.96 USD +0.0616

NVIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVIV.
View Industry Companies
 

Industry Analysis

NVIV

Industry Average

Valuation NVIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INVIVO THERAPEUTICS HOLDINGS, please visit www.invivotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.